Background: Increasing evidence has suggested that the host
inflammatory status is associated with the prognosis of a number of solid
tumours and that many cancers are inflammation-related. Preoperative
neutrophil-to-lymphocyte ratio (NLR) turned out to be a routinely available
prognostic biomarker, useful predictor of postoperative survival for patients
with various tumours, including gastric cancer (GC). However, there are some
doubts concerning the prognostic value of preoperative NLR. GC is a tumour type
that grows in the anatomical vicinity of adipose tissue, expansion of which
causes adipose dysfunction and inflammation to increase systemic levels of
proinflammatory factors. A key role in this mechanism seems to be played by the
onset of low-grade systemic inflammation.
Aim: The aim of this study was to find out whether there is
a relationship between the prognosis of disease outcome due to the value of NLR
and the density of adipocites (CAAs) in the primary tumor of patients with GC.
Materials and Methods: A total of 171 patients with GC were
eligible for retrospective analysis between 2009 and 2015. NLR was easily
obtained from a routine peripheral blood test. Immunohistochemical examination
of tumour tissue has been applied. All statistical analyses were conducted.
Results: The Low prognostic value of NLR is the most
reliable for the favourable outcome for patients having a low density of CAAs
in tumour. Patients with a high density of CAAs have a very high risk of dying,
and that does not depend on the value of NLR.
Conclusion: Prognosis due to the value of preoperative NLR
is essentially modified by the tumour CAA density, which is the basis for
additional identification of patients with an unfavourable outcome of disease
and the risk of mortality. It is the evidence for the expediency of the
evaluation of tumour CAA density in operation material, and clinicians need to
consider tumour CAA density for decisions on treatment strategy.
Author(s) Details
L. Bubnovskaya
R. E. Kavetsky Institute of Experimental Pathology, Oncology and
Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine.
I. Ganusevich
R. E. Kavetsky Institute of Experimental Pathology, Oncology and
Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine.
S. Merentsev
City Clinical Oncological Center, Kyiv, Ukraine.
D. Osinsky
City Clinical Oncological Center, Kyiv, Ukraine.
Please see the book here:- https://doi.org/10.9734/bpi/aodhr/v5/5876
No comments:
Post a Comment